Fennec Pharmaceuticals (NASDAQ:FENC) Rating Increased to Strong-Buy at Stephens

Stephens upgraded shares of Fennec Pharmaceuticals (NASDAQ:FENC) to a strong-buy rating in a research note released on Monday morning,Zacks.com reports.

Other analysts also recently issued reports about the company. Craig Hallum decreased their price target on Fennec Pharmaceuticals from $17.00 to $15.00 and set a “buy” rating for the company in a research report on Wednesday, August 14th. HC Wainwright cut their target price on Fennec Pharmaceuticals from $15.00 to $13.00 and set a “buy” rating for the company in a research note on Thursday, August 22nd. Finally, Wedbush restated an “outperform” rating and issued a $13.00 price objective (down from $14.00) on shares of Fennec Pharmaceuticals in a research report on Thursday, November 7th.

Fennec Pharmaceuticals Trading Up 5.9 %

FENC opened at $4.28 on Monday. Fennec Pharmaceuticals has a twelve month low of $3.96 and a twelve month high of $11.92. The company has a quick ratio of 7.64, a current ratio of 7.80 and a debt-to-equity ratio of 9.86. The company has a fifty day moving average of $4.70 and a 200-day moving average of $5.89. The stock has a market cap of $117.26 million, a PE ratio of -42.75 and a beta of 0.27.

Institutional Investors Weigh In On Fennec Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of FENC. State Street Corp grew its position in Fennec Pharmaceuticals by 2.2% during the 3rd quarter. State Street Corp now owns 328,259 shares of the company’s stock worth $1,641,000 after purchasing an additional 7,053 shares during the last quarter. Gendell Jeffrey L raised its holdings in shares of Fennec Pharmaceuticals by 7.1% during the 1st quarter. Gendell Jeffrey L now owns 302,478 shares of the company’s stock worth $3,364,000 after acquiring an additional 20,000 shares during the period. Bank of New York Mellon Corp lifted its holdings in Fennec Pharmaceuticals by 42.8% in the second quarter. Bank of New York Mellon Corp now owns 68,724 shares of the company’s stock valued at $420,000 after acquiring an additional 20,602 shares during the last quarter. WINTON GROUP Ltd purchased a new position in Fennec Pharmaceuticals during the second quarter worth about $409,000. Finally, Advantage Alpha Capital Partners LP acquired a new stake in shares of Fennec Pharmaceuticals in the third quarter valued at $264,000. 55.51% of the stock is owned by institutional investors.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc, a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children.